Advance in studies on pathological mechanism of Parkinson's disease and traditional Chinese medicine experiments in prevention and treatment of Parkinson's disease

Zhongguo Zhongyao Zazhi

Volumn 37, Issue 5, 2012, Pages 686-691

  Xiong, Pei ^a   Chen, Xin ^a   Zhanc, Nan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Nervous and mental pharmacology; Parkinson's disease; Treatment of traditional chinese medicine

Indexed keywords

APOPTOSIS; CHINESE MEDICINE; ENERGY METABOLISM; IMMUNE RESPONSE; INFLAMMATION; MITOCHONDRIAL RESPIRATION; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; REVIEW;

ANIMALS; APOPTOSIS; HUMANS; MEDICINE, CHINESE TRADITIONAL; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84861860523     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20120527     Document Type: Review

References (70)

1. Dario Acuña-Castroviejo, Ana Coto-Montes, M Gaia Monti, et al. Melatonin is protective against MPTP induced striatal and hippocampal lesions[J]. Life Sci, 1997,60(2):23.
2. Shoffner J M, Watts R L, Juncos J L, et al. Mitochondrial oxidative phosphorylation defects in Parkinson's disease[J]. Ann Neurol, 1991,30(3):332.
3. Parker W D, Boyson S T, Parks J K. Abnormalities of electron transport chain in idiopathic Parkinson's disease[J]. Ann Neurol, 1989,26(6):719.
4. Tada-Oikawa S, Hiraku Y, Kawanishi M, et al. Mechanism for generation of hydrogen peroxide and change of mitochondrial membrane potential during rotenone-induced apoptosis[J]. Life Sci, 2003,73(25):3277.
5. Bonuccelli V, Del Dotto P. New pharmacology horizons in the treatment of Parkinson disease[J]. Neurology, 2006,67(7):530.
6. Papa S B I, Chase T M. Levodopa-induced dyskinesias improved by glutamate antagonist in parkinsonian monkeys[J]. Ann Neurol, 1996,39:574.
7. Mattson M P. Excitotoxie and exeitoproteetive mechanisms : a-bundant targets for the prevention and treatment of neurodegenerative disorders [J]. Neuromol Med, 2003,3(2):65.
8. Hallett P J, Standaert D G. Rationale for and use of NMDA receptor antagonists in Parkinson's disease[J]. Pharmacol Ther, 2004,102(2):155.
9. Strugstad E, Sager G. Mechanisms behind drug dependence[J]. Tidsskr Nor Lageforen, 1998,118(12):1866.
10. Depino A M, Earl C, Kaczmarczyk E, et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease[J]. Eur J Neurosci, 2003,18(10):2731.
11. McGeer E G, McGeer P L. The role of the immune system in neurodegenerative disorders[J]. Mov Disord, 1997,12(6):855.
12. Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, et al. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine(MPTP)[J]. Immunopharmacology, 1998,39(3):167.
13. Hirsch E C, Hunots, Damier P, et al. Glia and inflammation in Parkinson's disease: a role in neurodegeneration[J]. Ann Neurol, 1998,44(3):S115.
14. Dauer W, Praedborsk S. Parkinson's disease; mechanisms and models[J]. Neuron, 2003,39(6):889.
15. Lorenzo A, Yankner B A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red[J]. Proc Natl Acad Sci USA, 1994,91(25):12243.
16. Ferro M M, Bellissimo M L, Anselmo-Franci J A, et al. Comparison of bilaterally 6-OHDA and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations[J]. J Neurosci Methods, 2005,148(1):78.
17. Hartmann A, Hunot S, Michel P P, et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease[J]. Natl Acad Sci USA, 2000,97(6):2875.